Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Nov 23, 2024
Finance
ATB’s €54M series A among largest ever in Belgium
BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
BioCentury | Oct 3, 2024
Discovery & Translation
Type 2 cytokines for durable cancer remission, drugging GTPases: BioCentury’s Science Spotlight
BioCentury’s roundup of translational innovations
BioCentury | Sep 12, 2024
Product Development
Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd
Plus: Results from Relay, Centessa, Viridian, Amgen and more
BioCentury | Feb 8, 2024
Product Development
Bristol Myers’ growing challenge
The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff
BioCentury | Oct 23, 2023
Deals
Oct. 23 Quick Takes: Merck drops two Kelun ADCs
Plus: FDA guidance facilitates communication about off-label uses and updates from Verve, Celltrion, Sanofi, Regeneron, Revolution, Harpoon, Aligos
BioCentury | Aug 8, 2023
Emerging Company Profile
Recludix: targeting STATs via their SH2 domains
San Diego company’s STAT6 program is partnered with Sanofi
BioCentury | Jan 14, 2023
Discovery & Translation
Ubiquitin-regulation for tauopathies; plus Regeneron’s IL2RG mAb for T cell-driven disease and more
BioCentury’s round-up of translational news
BioCentury | Jun 1, 2022
Data Byte
June’s PDUFA dates no longer include Amylyx’s ALS therapy
At least three new therapies and four seeking label extensions have PDUFA goal dates in June
BioCentury | Jul 8, 2021
Finance
Keymed’s first-day valuation tops $2B after pricing Hong Kong IPO
Public investors welcomed Keymed with a warm reception on the Hong Kong stock exchange, signaling confidence in a pipeline that includes the Chinese biotech’s potential Dupixent competitor. In
Items per page:
1 - 10 of 41